Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wen Dong, Pengfei Lei, Xin Liu, Qin Li, Xiangyang Cheng
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
lung cancer
EML4-ALK
nivolumab
complete remission
PD-L1
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/c47edd3d89c54a13a5741f48b45b0d71
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c47edd3d89c54a13a5741f48b45b0d71

Ejemplares similares